95 related articles for article (PubMed ID: 15261284)
1. The development of novel inhibitors of tumor necrosis factor-alpha (TNF-alpha) production based on substituted [5,5]-bicyclic pyrazolones.
Laufersweiler MJ; Brugel TA; Clark MP; Golebiowski A; Bookland RG; Laughlin SK; Sabat MP; Townes JA; VanRens JC; De B; Hsieh LC; Heitmeyer SA; Juergens K; Brown KK; Mekel MJ; Walter RL; Janusz MJ
Bioorg Med Chem Lett; 2004 Aug; 14(16):4267-72. PubMed ID: 15261284
[TBL] [Abstract][Full Text] [Related]
2. The development of monocyclic pyrazolone based cytokine synthesis inhibitors.
Golebiowski A; Townes JA; Laufersweiler MJ; Brugel TA; Clark MP; Clark CM; Djung JF; Laughlin SK; Sabat MP; Bookland RG; VanRens JC; De B; Hsieh LC; Janusz MJ; Walter RL; Webster ME; Mekel MJ
Bioorg Med Chem Lett; 2005 May; 15(9):2285-9. PubMed ID: 15837310
[TBL] [Abstract][Full Text] [Related]
3. Development of orally bioavailable bicyclic pyrazolones as inhibitors of tumor necrosis factor-alpha production.
Clark MP; Laughlin SK; Laufersweiler MJ; Bookland RG; Brugel TA; Golebiowski A; Sabat MP; Townes JA; VanRens JC; Djung JF; Natchus MG; De B; Hsieh LC; Xu SC; Walter RL; Mekel MJ; Heitmeyer SA; Brown KK; Juergens K; Taiwo YO; Janusz MJ
J Med Chem; 2004 May; 47(11):2724-7. PubMed ID: 15139749
[TBL] [Abstract][Full Text] [Related]
4. The development of new bicyclic pyrazole-based cytokine synthesis inhibitors.
Townes JA; Golebiowski A; Clark MP; Laufersweiler MJ; Brugel TA; Sabat M; Bookland RG; Laughlin SK; VanRens JC; De B; Hsieh LC; Xu SC; Janusz MJ; Walter RL
Bioorg Med Chem Lett; 2004 Oct; 14(19):4945-8. PubMed ID: 15341957
[TBL] [Abstract][Full Text] [Related]
5. Development of N-2,4-pyrimidine-N-phenyl-N'-alkyl ureas as orally active inhibitors of tumor necrosis factor alpha (TNF-alpha) synthesis. Part 2.
Maier JA; Brugel TA; Clark MP; Sabat M; Golebiowski A; Bookland RG; Laufersweiler MJ; Laughlin SK; Vanrens JC; De B; Hsieh LC; Brown KK; Juergens K; Walter RL; Janusz MJ
Bioorg Med Chem Lett; 2006 Jul; 16(13):3514-8. PubMed ID: 16632350
[TBL] [Abstract][Full Text] [Related]
6. Development of N-2,4-pyrimidine-N-phenyl-N'-phenyl ureas as inhibitors of tumor necrosis factor alpha (TNF-alpha) synthesis. Part 1.
Brugel TA; Maier JA; Clark MP; Sabat M; Golebiowski A; Bookland RG; Laufersweiler MJ; Laughlin SK; Vanrens JC; De B; Hsieh LC; Mekel MJ; Janusz MJ
Bioorg Med Chem Lett; 2006 Jul; 16(13):3510-3. PubMed ID: 16632356
[TBL] [Abstract][Full Text] [Related]
7. The development of new isoxazolone based inhibitors of tumor necrosis factor-alpha (TNF-alpha) production.
Laughlin SK; Clark MP; Djung JF; Golebiowski A; Brugel TA; Sabat M; Bookland RG; Laufersweiler MJ; VanRens JC; Townes JA; De B; Hsieh LC; Xu SC; Walter RL; Mekel MJ; Janusz MJ
Bioorg Med Chem Lett; 2005 May; 15(9):2399-403. PubMed ID: 15837333
[TBL] [Abstract][Full Text] [Related]
8. The development of novel C-2, C-8, and N-9 trisubstituted purines as inhibitors of TNF-alpha production.
Sabat M; Vanrens JC; Clark MP; Brugel TA; Maier J; Bookland RG; Laufersweiler MJ; Laughlin SK; Golebiowski A; De B; Hsieh LC; Walter RL; Mekel MJ; Janusz MJ
Bioorg Med Chem Lett; 2006 Aug; 16(16):4360-5. PubMed ID: 16750367
[TBL] [Abstract][Full Text] [Related]
9. 1,2,3-Thiadiazole substituted pyrazolones as potent KDR/VEGFR-2 kinase inhibitors.
Tripathy R; Ghose A; Singh J; Bacon ER; Angeles TS; Yang SX; Albom MS; Aimone LD; Herman JL; Mallamo JP
Bioorg Med Chem Lett; 2007 Mar; 17(6):1793-8. PubMed ID: 17239587
[TBL] [Abstract][Full Text] [Related]
10. Leptin enhances TNF-alpha production via p38 and JNK MAPK in LPS-stimulated Kupffer cells.
Shen J; Sakaida I; Uchida K; Terai S; Okita K
Life Sci; 2005 Aug; 77(13):1502-15. PubMed ID: 15979653
[TBL] [Abstract][Full Text] [Related]
11. Discovery and structure-activity relationship of coumarin derivatives as TNF-alpha inhibitors.
Cheng JF; Chen M; Wallace D; Tith S; Arrhenius T; Kashiwagi H; Ono Y; Ishikawa A; Sato H; Kozono T; Sato H; Nadzan AM
Bioorg Med Chem Lett; 2004 May; 14(10):2411-5. PubMed ID: 15109623
[TBL] [Abstract][Full Text] [Related]
12. 5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase.
Liu C; Wrobleski ST; Lin J; Ahmed G; Metzger A; Wityak J; Gillooly KM; Shuster DJ; McIntyre KW; Pitt S; Shen DR; Zhang RF; Zhang H; Doweyko AM; Diller D; Henderson I; Barrish JC; Dodd JH; Schieven GL; Leftheris K
J Med Chem; 2005 Oct; 48(20):6261-70. PubMed ID: 16190753
[TBL] [Abstract][Full Text] [Related]
13. Adenosine A2A receptor agonists inhibit lipopolysaccharide-induced production of tumor necrosis factor-alpha by equine monocytes.
Sun WC; Moore JN; Hurley DJ; Vandenplas ML; Linden J; Cao Z; Murray TF
Vet Immunol Immunopathol; 2008 Jan; 121(1-2):91-100. PubMed ID: 17913243
[TBL] [Abstract][Full Text] [Related]
14. Biological evaluation of novel 6-Arylbenzimidazo[1,2-c]quinazoline derivatives as inhibitors of LPS-induced TNF-alpha secretion.
Galarce GD; Foncea RE; Edwards AM; Pessoa-Mahana H; Pessoa-Mahana CD; Ebensperger RA
Biol Res; 2008; 41(1):43-50. PubMed ID: 18769762
[TBL] [Abstract][Full Text] [Related]
15. A small compound that inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production.
Kim JI; Lee HY; Park KS; Lee T; Ryu SH; Bae YS
Biochem Biophys Res Commun; 2006 Sep; 347(3):797-802. PubMed ID: 16842752
[TBL] [Abstract][Full Text] [Related]
16. SA13353 (1-[2-(1-Adamantyl)ethyl]-1-pentyl-3-[3-(4-pyridyl)propyl]urea) inhibits TNF-alpha production through the activation of capsaicin-sensitive afferent neurons mediated via transient receptor potential vanilloid 1 in vivo.
Murai M; Tsuji F; Nose M; Seki I; Oki K; Setoguchi C; Suhara H; Sasano M; Aono H
Eur J Pharmacol; 2008 Jul; 588(2-3):309-15. PubMed ID: 18508045
[TBL] [Abstract][Full Text] [Related]
17. The development of new triazole based inhibitors of tumor necrosis factor-alpha (TNF-alpha) production.
Tullis JS; VanRens JC; Natchus MG; Clark MP; De B; Hsieh LC; Janusz MJ
Bioorg Med Chem Lett; 2003 May; 13(10):1665-8. PubMed ID: 12729637
[TBL] [Abstract][Full Text] [Related]
18. Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.
de Dios A; Shih C; López de Uralde B; Sánchez C; del Prado M; Martín Cabrejas LM; Pleite S; Blanco-Urgoiti J; Lorite MJ; Nevill CR; Bonjouklian R; York J; Vieth M; Wang Y; Magnus N; Campbell RM; Anderson BD; McCann DJ; Giera DD; Lee PA; Schultz RM; Li LC; Johnson LM; Wolos JA
J Med Chem; 2005 Apr; 48(7):2270-3. PubMed ID: 15801819
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological activity of N,N-dialkylaminoalkyl-substituted bisindolyl and diphenyl pyrazolone derivatives.
Braña MF; Gradillas A; Ovalles AG; López B; Acero N; Llinares F; Muñoz Mingarro D
Bioorg Med Chem; 2006 Jan; 14(1):9-16. PubMed ID: 16263294
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
Hynes J; Dyckman AJ; Lin S; Wrobleski ST; Wu H; Gillooly KM; Kanner SB; Lonial H; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Yang X; Zhang R; Behnia K; Zhang H; Marathe PH; Doweyko AM; Tokarski JS; Sack JS; Pokross M; Kiefer SE; Newitt JA; Barrish JC; Dodd J; Schieven GL; Leftheris K
J Med Chem; 2008 Jan; 51(1):4-16. PubMed ID: 18072718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
